However, following the adjustment for age, gender, vascular risk factors, presence of triple-positive aPL, previous history of recurrent thrombosis and time in therapeutic range of anticoagulation with VKAs, there was no effect of HCQ towards reducing the risk of recurrent thrombosis. This evidence concerns the gene FASLG and deep vein thrombosis.